<DOC>
	<DOCNO>NCT02437487</DOCNO>
	<brief_summary>The study involve administer study drug single dose study drug placebo . This study design demonstrate superiority experimental drug versus placebo adult patient recurrent CDI .</brief_summary>
	<brief_title>SER-109 Versus Placebo Prevent Recurrent Clostridium Difficile Infection ( RCDI )</brief_title>
	<detailed_description>ECOSPOR Phase 2 , multicenter , randomize , double blind , placebo control clinical study 2 treatment arm ( SER-109 placebo ) . Patients diarrhea positive C. difficile test result stool sample , respond standard care antibiotic treatment receive study drug Day 1 . Those patient experience recurrence CDI 8 week SER 109 placebo treatment offer opportunity enroll open label SER 109 extension study ( Study SERES 005 ) .</detailed_description>
	<criteria>1 . Signed informed consent , indicate patient understands purpose procedure require study . Patients unable provide inform consent include study . 2 . Male female patient ≥ 18 year . 3 . ≥ 3 episode CDI within previous 9 month , inclusive current episode documentation ≥ 2 episode . 1 . Female patient pregnant , breastfeeding , lactate , plan become pregnant study . 2 . Known suspected toxic megacolon and/or know small bowel ileus . 3 . Active irritable bowel syndrome diarrhea within previous 12 month . 4 . Major gastrointestinal surgery ( eg , significant bowel resection diversion ) within 3 month enrollment ( include appendectomy cholecystectomy ) history total colectomy bariatric surgery . 5 . History inflammatory bowel disease ( ulcerative colitis , Crohn 's disease , microscopic colitis ) diarrhea believe cause active inflammatory bowel disease past 24 month . 6 . Admitted expect admitted acute care facility intensive care unit medical reason ( board ) . Patients discharge acute care facility Day 1 reside nursing home rehabilitation facility may enrol . 7 . Concurrent intensive induction chemotherapy , radiotherapy , biologic treatment active malignancy ( patient maintenance chemotherapy may enrol consultation medical monitor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>